Phase 3 Clinical Trials With Primary Completion Dates in October 2016

This is a list of Phase 3 trials with primary completion dates in October 2016 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ADHD Alcobra Ltd. 2016-10-01 Phase 3 NCT02477748 The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
AEZS AEterna Zentaris Inc. 2016-10-01 Phase 3 NCT02558829 Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency
ALKS Alkermes plc 2016-10-01 Phase 3 NCT02218008 A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study
CYNA Cynapsus Therapeutics Inc. 2016-10-01 Phase 3 NCT02469090 A Phase 3 Study to Examine the Efficacy, Safety and Tolerability of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease
EXEL Exelixis, Inc. 2016-10-01 Phase 3 NCT01908426 Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
FOLD Amicus Therapeutics, Inc. 2016-10-01 Phase 3 NCT01476163 Physician Initiated Request for Migalastat in Individual Patients With Fabry Disease
INSM Insmed, Inc. 2016-10-01 Phase 3 NCT02344004 Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone
ITEK Inotek Pharmaceuticals Corporation 2016-10-01 Phase 3 NCT02565173 Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma
MNK Mallinckrodt plc 2016-10-01 Phase 3 NCT02321319 Open-Label Safety and PK Study of ER Hydromorphone Tablets in Opioid-Tolerant Pediatric Chronic Pain Patients
MNK Mallinckrodt plc 2016-10-01 Phase 3 NCT02132195 Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome
NEOT Neothetics, Inc. 2016-10-01 Phase 3 NCT02483533 Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202
NURO NeuroMetrix, Inc. 2016-10-01 Phase 3 NCT02809846 Quell Opioid Reduction and Pain Relief in Patients With Cancer
RDUS Radius Health, Inc. 2016-10-01 Phase 3 NCT01657162 Twenty Four Month Extension Study of BA058-05-003
TENX Tenax Therapeutics, Inc. 2016-10-01 Phase 3 NCT02025621 Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass
TXMD TherapeuticsMD, Inc. 2016-10-01 Phase 3 NCT01942668 A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms
VRX Valeant Pharmaceuticals International, Inc. 2016-10-01 Phase 3 NCT02462122 Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
VRX Valeant Pharmaceuticals International, Inc. 2016-10-01 Phase 3 NCT02462070 Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis